MRD Detection for Colorectal Cancer
(MRD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a method to detect remaining cancer cells after surgery for colorectal cancer, which affects the colon or rectum. It focuses on patients who have undergone successful surgery to remove stage II or III colorectal cancer. The study monitors patients for up to seven years to determine if this method aids in detecting cancer recurrence. Suitable candidates have had their colorectal cancer completely removed in surgery within the last six months and have not yet started additional cancer treatment. Participants must provide blood samples and comply with study requirements. The trial uses MRD (minimal residual disease) detection to identify any remaining cancer cells.
As a Phase 2 trial, this research measures the effectiveness of the detection method in an initial, smaller group, offering participants the opportunity to contribute to potentially groundbreaking advancements in cancer monitoring.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Why are researchers excited about this trial?
Researchers are excited about the Minimal Residual Disease (MRD) detection method in colorectal cancer because it offers a way to identify remaining cancer cells that might not be visible through traditional imaging. Most treatments for colorectal cancer, like surgery, chemotherapy, and radiation, focus on removing or killing visible tumors. However, MRD detection stands out by focusing on the microscopic level to catch cancer cells early, potentially preventing relapse. This innovative approach could lead to more personalized treatment plans and improve long-term outcomes for patients with stage II or III colorectal cancer.
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Post-Surgical Monitoring
Participants are monitored for minimal residual disease using a circulating tumor DNA assay after complete surgical resection
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- MRD
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Patients with stage ll or lll colorectal cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Exact Sciences Corporation
Lead Sponsor
NSABP Foundation Inc
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.